In the breast cancer tumor model, metformin activates AMPK in tumor cells, which directly binds to and phosphorylates PD-L1 at S195, inducing abnormal PD-L1 glycosylation and leading to degradation of PD-L1 by ER-associated protein degradation (ERAD). The gene discussed is CD274; the disease is breast carcinoma.